Latin America sets out to end neglect of rare diseases

Myriam Vidal Valero

DOI: https://doi.org/10.1126/science.adu2387

IF: 56.9

2024-11-01

Science

Abstract:Network aims to raise awareness and bolster testing and treatment for rare genetic conditions

multidisciplinary sciences

What problem does this paper attempt to address?

Discovery of novel genetic syndromes in Latin America: Opportunities and challenges

Víctor Faundes,Gabriela M. Repetto,Leonardo E. Valdivia,Valdivia,Leonardo E.

DOI: https://doi.org/10.1590/1678-4685-gmb-2023-0318

2024-03-11

Genetics and Molecular Biology

Abstract:Faundes, Víctor ; Repetto, Gabriela M. ; Valdivia, Leonardo E. ; Latin America (LatAm) has a rich and historically significant role in delineating both novel and well-documented genetic disorders. However, the ongoing advancements in the field of human genetics pose challenges to the relatively slow adaption of LatAm in the field. Here, we describe past and present contributions of LatAm to the discovery of novel genetic disorders, often referred as novel gene-disease associations (NGDA). We also describe the current methodologies for discovery of NGDA, taking into account the latest developments in genomics. We provide an overview of opportunities and challenges for NGDA research in LatAm considering the steps currently performed to identify and validate such associations. Given the multiple and diverse needs of populations and countries in LatAm, it is imperative to foster collaborations amongst patients, indigenous people, clinicians and scientists. Such collaborative effort is essential for sustaining and enhancing the LatAm ́s contributions to the field of NGDA.

genetics & heredity,biochemistry & molecular biology
The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America

Renée J.G. Arnold,Lida Bighash,Alejandro Bryón Nieto,Gabriela Tannus Branco de Araújo,Juan Gabriel Gay-Molina,Federico Augustovski

DOI: https://doi.org/10.12688/f1000research.4268.1

2015-02-27

F1000Research

Abstract:Compared to a decade ago, nearly three times as many drugs for rare diseases are slated for development. This article addresses the market access issues associated with orphan drug status in Europe and the United States in contrast to the legislation in five Latin American (LA) countries that have made strides in this regard--Mexico, Brazil, Colombia, Chile and Argentina. Based on the success of orphan drug legislation in the EU and US, LA countries should strive to adopt similar strategies with regard to rare diseases and drug development. With the implementation of new targeted regulations, reimbursement strategies, and drug approvals, accessibility to treatment will be improved for people afflicted with rare diseases in these developing countries.
Building a National Policy for Rare Disease in Brazil

Têmis Maria Félix,Bibiana Mello de Oliveira,Dafne Dain Gandelman Horovitz

DOI: https://doi.org/10.1007/s12687-024-00732-9

2024-09-26

Abstract:Rare diseases (RD) are individually rare, although encompass a significant proportion of the population, affecting not only the individuals but also their families. In Brazil RD is defined by the Ministry of Health as a disorder that affects up to 65 individuals in 100,000, or 1.3 individuals in every 2,000. In this review the environment that led to the publication of a National Policy for Comprehensive Care for People of Rare Disease in 2014, a national plan with the aim to decrease morbidity and mortality of RD, improving the care of people with RD in the public health system are described. The process that finally led to such policy took over a decade, moving forward not only due to technical needs, but having patient organizations as essential actors and advocates. Specialized centers in RD were licensed and, since its publication, 33 centers have been accredited; such process, however, has been slow and concentrated in specific regions and larger cities of the country. Despite the incorporation of genetic tests in 2014 and exome sequencing later in 2020, many genetic tests are not offered by specialized centers, with unequal availability across the country. Public health system in Brazil uses ICD-10 for disease coding, preventing appropriate epidemiologic knowledge of RD in Brazil. Incorporation of new technologies as orphan drugs has been in place and regulation for expedite licensing for new RD drugs were issued, although high cost and availability to RD population has been a challenge.
Global Health for Rare Diseases Through Primary Care

Gareth Baynam,Adam L. Hartman,Mary Catherine Letinturier,Matt Bolz-Johnson,Prescilla Carrion,Alice Chen Grady,Xinran Dong,Marc Dooms,Lauren Dreyer,Holm Graessner,Alicia Granados,Tudor Groza,Elisa Houwink,Saumya Shekhar Jamuar,Tania Vasquez-Loarte,Birute Tumiene,Samuel Agyei Wiafe,Heidi Bjornson-Pennell,Stephen Groft

DOI: https://doi.org/10.1016/s2214-109x(24)00134-7

2024-01-01

Abstract:Rare diseases affect over 300 million people worldwide and are gaining recognition as a global health priority. Their inclusion in the UN Sustainable Development Goals, the UN Resolution on Addressing the Challenges of Persons Living with a Rare Disease, and the anticipated WHO Global Network for Rare Diseases and WHO Resolution on Rare Diseases, which is yet to be announced, emphasise their significance. People with rare diseases often face unmet health needs, including access to screening, diagnosis, therapy, and comprehensive health care. These challenges highlight the need for awareness and targeted interventions, including comprehensive education, especially in primary care. The majority of rare disease research, clinical services, and health systems are addressed with specialist care. WHO Member States have committed to focusing on primary health care in both universal health coverage and health-related Sustainable Development Goals. Recognising this opportunity, the International Rare Diseases Research Consortium (IRDiRC) assembled a global, multistakeholder task force to identify key barriers and opportunities for empowering primary health-care providers in addressing rare disease challenges.
[Rare diseases and undiagnosed diseases: advances in neurodevelopment]

María Teresa Acosta

Abstract:Rare diseases and undiagnosed diseases have recently positioned themselves as clinical entities that provide important opportunities to advance our understanding of gene functions and the impact of them in the individual development. In this review, we present how efforts made over years to understand common diseases, rare diseases and even undiagnosed diseases come together today to cooperatively advances scientific knowledge. These advance in science and new acquired knowledge, make possible to apply the advances obtained in a group of clinical conditions to others with similar phenotypic characteristics or vice versa. The cooperative work of multidisciplinary teams and the communication between clinicians and researchers have and will provide opportunities for better treatments for patients and families across multiple common and rare diseases.
Special Issue "Diagnosis and Treatment of Rare Diseases"

Álvaro Hermida-Ameijeiras

DOI: https://doi.org/10.3390/jcm13092574

IF: 3.9

2024-04-28

Journal of Clinical Medicine

Abstract:Rare diseases (RDs) represent a large and heterogeneous group of low-prevalence conditions, and 473 million people could be affected worldwide [...]

medicine, general & internal
Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Clio Rubinos,Daniel San-Juan,Carlos Alva-Diaz,Jorge Burneo,Andres Fernandez,Luis Carlos Mayor-Romero,Jorge Vidaurre,Loreto Rios-Pohl,Maria Jose Bruzzone,Bruzzone,Maria Jose

DOI: https://doi.org/10.1055/s-0044-1782616

2024-03-29

Seminars in Neurology

Abstract:The burden of epilepsy in the Latin America and the Caribbean (LAC) region causes a profound regional impact on the health care system and significantly contributes to the global epilepsy burden. As in many other resource-limited settings worldwide, health care professionals and patients with epilepsy in LAC countries face profound challenges due to a combination of factors, including high disease prevalence, stigmatization of epilepsy, disparities in access to care, limited resources, substantial treatment gaps, insufficient training opportunities for health care providers, and a diverse patient population with varying needs. This article presents an overview of the epidemiology of epilepsy and discusses the principal obstacles to epilepsy care and key contributors to the epilepsy diagnosis and treatment gap in the LAC region. We conclude by highlighting various initiatives across different LAC countries to improve epilepsy care in marginalized communities, listing strategies to mitigate treatment gaps and facilitate better health care access for patients with epilepsy by enhancing the epilepsy workforce. Article published online: 27 March 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

clinical neurology
Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement

Luis Antonio Díaz,Gustavo Ayares,Jorge Arnold,Francisco Idalsoaga,Oscar Corsi,Marco Arrese,Juan Pablo Arab

DOI: https://doi.org/10.1007/s11938-022-00382-1

2022-06-16

Current Treatment Options in Gastroenterology

Abstract:AbstractPurpose of reviewTo assess the current challenges regarding liver diseases, including the burden of disease, access to care, screening, and treatment needs in Latin America.Recent findingsLatin America is a region with a rich multicultural heritage and important socioeconomic differences. The burden of liver diseases is high and mainly determined by a high level of alcohol intake and the surge of risk factors associated with NAFLD (i.e., sedentary lifestyles, broader access to highly processed foods, obesity, and type 2 diabetes mellitus). Hepatotropic viruses also play a role in the development of chronic liver diseases, although their comparative frequency has been decreasing over the last decades. There are important disparities in access to screening and treatment for liver diseases in Latin America, which are reflected in low access to critical treatments such as direct-acting antiviral agents and drugs to treat hepatocellular carcinoma. Also, important barriers to liver transplantation are present in multiple countries, including a low deceased donors’ rate and a lack of availability in several countries (especially in Central America). Our region also has disadvantages in research and education in liver diseases, which limits regional academic development and improvement in quality of care of liver diseases.SummaryIn order to tackle an increasing health burden due to liver diseases, Latin America urgently needs tailored interventions aiming to control the main risk factors for these disorders through the establishment of effective public health policies. Also, development of liver transplantation programs and improvement of medical education and research capabilities as well as extensive collaboration between all stakeholders are keys to address the liver disease agenda in the region.
Advancing diagnosis and research for rare genetic diseases in Indigenous peoples

Gareth Baynam,Daria Julkowska,Sarah Bowdin,Azure Hermes,Christopher R. McMaster,Elissa Prichep,Étienne Richer,Francois H. van der Westhuizen,Gabriela M. Repetto,Helen Malherbe,Juergen K. V. Reichardt,Laura Arbour,Maui Hudson,Kelly du Plessis,Melissa Haendel,Phillip Wilcox,Sally Ann Lynch,Shamir Rind,Simon Easteal,Xavier Estivill,Nadine Caron,Meck Chongo,Yarlalu Thomas,Mary Catherine V. Letinturier,Barend Christiaan Vorster

DOI: https://doi.org/10.1038/s41588-023-01642-1

IF: 30.8

2024-02-10

Nature Genetics

Abstract:Achieving a diagnosis for Indigenous people living with a rare, often genetic, disease is crucial for equitable healthcare. The International Rare Disease Research Consortium convened a global Task Force to bridge the gap in diagnosing Indigenous rare diseases, and identify solutions to tackle the health inequity faced by Indigenous people.

genetics & heredity
The importance of international collaboration for rare diseases research: a European perspective

D Julkowska,C P Austin,C M Cutillo,D Gancberg,C Hager,J Halftermeyer,A H Jonker,L P L Lau,I Norstedt,A Rath,R Schuster,E Simelyte,S van Weely

DOI: https://doi.org/10.1038/gt.2017.29

2017-07-27

Gene Therapy

Abstract:Over the last two decades, important contributions were made at national, European and international levels to foster collaboration into rare diseases research. The European Union (EU) has put much effort into funding rare diseases research, encouraging national funding organizations to collaborate together in the E-Rare program, setting up European Reference Networks for rare diseases and complex conditions, and initiating the International Rare Diseases Research Consortium (IRDiRC) together with the National Institutes of Health in the USA. Co-ordination of the activities of funding agencies, academic researchers, companies, regulatory bodies, and patient advocacy organizations and partnerships with, for example, the European Research Infrastructures maximizes the collective impact of global investments in rare diseases research. This contributes to accelerating progress, for example, in faster diagnosis through enhanced discovery of causative genes, better understanding of natural history of rare diseases through creation of common registries and databases and boosting of innovative therapeutic approaches. Several examples of funded pre-clinical and clinical gene therapy projects show that integration of multinational and multidisciplinary expertize generates new knowledge and can result in multicentre gene therapy trials. International collaboration in rare diseases research is key to improve the life of people living with a rare disease.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
Rare diseases: Insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis

Rumiana Tenchov,Kavita Iyer,Janet Sasso,Krittika Ralhan,Jyotsna Jotshi,Dmitrii Polshakov,Ankush Maind,Qiongqiong Angela Zhou

DOI: https://doi.org/10.26434/chemrxiv-2024-rkqvt

2024-06-28

Abstract:Rare diseases are a diverse group of disorders that despite each individual condition's rarity, collectively affect a significant portion of the global population. Currently approximately 10,000 rare diseases exist globally, 80% of these diseases have been identified as of genetic origins. In this review, we examine data from the CAS Content Collection to summarize scientific progress in the area of rare diseases. We examine the publication landscape in the area in effort to provide insights into current advances and developments. We then discuss the evolution of key concepts in the field, genetic associations, as well as the major technologies and development pipelines of rare disease treatments. We focus our attention on three specific rare diseases: (i) amyotrophic lateral sclerosis, a terminal neurodegenerative disease affecting the central nervous system resulting in progressive loss of motor neurons that control voluntary muscles; (ii) Huntington’s disease, another terminal neurodegenerative disease that causes progressive degeneration of nerve cells in the brain, with a wide impact on a person's functional abilities; and (iii) myasthenia gravis, a chronic autoimmune synaptopathy leading to skeletal muscle weakness. While the pathogenesis of these rare diseases is being elucidated, there is neither a cure nor preventative treatment available, only symptomatic treatment. The objective of the paper is to provide a broad overview of the evolving landscape of current knowledge on rare diseases, to outline challenges, and evaluate growth opportunities, all with an aim to further efforts in solving the remaining challenges.

Chemistry
Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Rumiana Tenchov,Kavita Iyer,Janet Sasso,Krittika Ralhan,Jyotsna Jotshi,Dmitrii Polshakov,Ankush Maind,Qiongqiong Angela Zhou

DOI: https://doi.org/10.26434/chemrxiv-2024-rkqvt-v2

2024-08-12

Abstract:Rare diseases are a diverse group of disorders that despite each individual condition's rarity, collectively affect a significant portion of the global population. Currently approximately 10,000 rare diseases exist globally, with 80% of these diseases being identified as having genetic origins. In this review, we examine data from the CAS Content CollectionTM to summarize scientific progress in the area of rare diseases. We examine the publication landscape in the area in effort to provide insights into current advances and developments. We then discuss the evolution of key concepts in the field, genetic associations, as well as the major technologies and development pipelines of rare disease treatments. We focus our attention on three specific rare diseases: (i) amyotrophic lateral sclerosis, a terminal neurodegenerative disease affecting the central nervous system resulting in progressive loss of motor neurons that control voluntary muscles; (ii) Huntington’s disease, another terminal neurodegenerative disease that causes progressive degeneration of nerve cells in the brain, with a wide impact on a person's functional abilities; and (iii) myasthenia gravis, a chronic autoimmune synaptopathy leading to skeletal muscle weakness. While the pathogenesis of these rare diseases is being elucidated, there is neither a cure nor preventative treatment available, only symptomatic treatment. The objective of the paper is to provide a broad overview of the evolving landscape of current knowledge on rare diseases, and specifically on the biology and genetics of the three spotlighted diseases, to outline challenges and evaluate growth opportunities, an aim to further efforts in solving the remaining challenges.

Chemistry
Child Neurology Care in Latin America: Challenges and Potential Solutions

Jorge A Vidaurre,Pedro Weisleder

DOI: https://doi.org/10.1016/j.pediatrneurol.2022.04.010

Abstract:Background: The current practice of child neurology in Latin America has been impacted by the waves of sociopolitical unrest that in the last decades have swept the region. Methods: We searched the available literature referring to the situation of child neurology in Latin America and conditions that specifically impact the region. Results: In lower-middle-income countries, the number of child neurologists is inadequate. Child neurologists working in large public hospitals can only afford to do so on a part-time basis as these institutions are chronically underfunded. Several circumstances are particularly relevant to Latin America: Spanish is the main language spoken, something that limits the opportunity to keep local child neurologists up to date. The structure of health care systems in Latin America varies significantly. Some countries have fragmented systems with inadequate capacity to offer equitable access to medical care. Latin America has been impacted by epidemics of arthropod-borne viruses: zika, chikungunya, and dengue. It stands to reason that the COVID-19 pandemic will affect the distribution of resources for chronic neurological conditions. Conclusions: The virtual platforms such as Zoom, expanded during the COVID-19 pandemic, are useful not only to improve access to care through telemedicine but also for educational purposes. Collaborative efforts to support educational courses and symposia in Spanish are ongoing. It is necessary to set short- and long-term priorities to improve child neurology care in the region. Immediate priorities should focus on improving the diagnosis of neurological conditions, making emphasis on locally available resources.
Editorial: Childhood leukemias in Latin America: epidemiology, causality, novel predictive profiles and therapeutic strategies

Juan Carlos Núñez-Enríquez,Juan Manuel Mejía-Aranguré,Mario Ernesto Cruz-Muñoz,Rosana Pelayo

DOI: https://doi.org/10.3389/fonc.2024.1509943

IF: 4.7

2024-11-27

Frontiers in Oncology

Abstract:Latin America is a geographic region that shares cultural and genetic characteristics that may influence the susceptibility of its population to various diseases, including acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, and acute promyelocytic leukemia (APL), which is also frequently observed among Hispanic populations (1). Notably, childhood ALL in Latino and Hispanic populations is associated with a lower frequency of gene rearrangements linked to favorable outcomes, alongside higher frequencies of gene patterns associated with poorer prognosis. Unfortunately, this corresponds with lower survival rates. It's important to recognize that the exact causes of leukemia are not fully understood, and only a limited number of risk factors have been identified (2)(3)(4)(5)(6).This Research Topic is devoted to current and in-progress scientific knowledge on epidemiological, biological and clinical aspects of acute leukemias in children and their control in the Latin American region. "Childhood Leukemias in Latin America: Epidemiology, Causality, Novel Predictive Profiles and Therapeutic Strategies" includes 17 Original Research articles, 2 Reviews, 1 Methods and 1 Perspective article, providing a comprehensive overview of the advancements in some of the malignant diseases that have been extremely heterogeneous and a cause of long-term diseases in Latin America.In this Research Topic, expert authors explore the epidemiology, causation, prevention, pathobiology, diagnosis, novel predictive profiles, and therapeutic strategies related to this significant health priority in Latin America, given the rising incidence and mortality rates at very early stages of treatment.Recent studies illuminate the genetic, environmental, and socioeconomic factors contributing to the high incidence rates of childhood leukemia in Latin America. This Research Topic includes a review of the role of genetic variation and Indigenous American ancestry in the etiology of childhood leukemias. It also discusses future research directions aimed at enhancing our understanding of the disparities in ALL incidence and outcomes among children of Latin American origin, insights that are crucial for informing future precision prevention efforts (de Smith et al).One notable study examined the interaction between specific genetic variants related to glucocorticoid secretion and birth characteristics in relation to ALL risk, building on previous hypotheses that endogenous cortisol may influence the elimination of preleukemic clones formed in utero. This study underscores the potential role of genes regulating the hypothalamic-pituitary-adrenal (HPA) axis in leukemia development, warranting further validation of these findings (de Carvalho et al).Additionally, a population-based study from Puebla, Tlaxcala, and Oaxaca reports incidence rates consistent with trends observed in other Latin American regions, identifying peaks for both lymphoblastic and myeloid leukemias. Variations among subregions may be linked to social and ethnic factors, highlighting the urgent need for targeted research into the socio-environmental determinants of leukemia (Flores-Lujano et al).A spatial analysis in Greater Mexico City further elucidates the potential environmental influences on leukemia incidence. Significant clustering of ALL cases is observed, with a relative risk indicating heightened incidence in identified clusters. Proximity to electrical installations and petrochemical facilities suggests that environmental factors contribute to leukemia risk, emphasizing the necessity for further investigation and preventive measures in high-risk areas (Duarte-Rodriguez et al). Moreover, in another research ALL clusters potentially associated with carcinogenic sources, leading to higher risks of poor outcomes were identified (Calderon-Hernández et al).Finally, two large case-control studies examine the impact of maternal diet during pregnancy on the risk of childhood leukemias in infants (Mérida-Ortega et al; Pérez-Saldívar et al)A study featured in this Research Topic employs comprehensive profiling tools to identify unique biomarkers and microenvironment characteristics, advocating for early and personalized risk stratification. This approach has the potential to significantly enhance treatment strategies and improve patient outcomes. The focus on patient stratification and risk prediction has provided valuable insights, particularly regarding a subtype of ProB-ALL in Mexican children from vulnerable regions, which is linked to a higher risk of measurable residual disease (MRD) (Romo-Rodriguez et al).In another study, the authors characterize the systemic immunological profile of children undergoing treatment for B-ALL, evaluating various cell populations, chemokines, and cytokines as potential biomarkers for clinical follow-up. Given the challenges of monitoring immune cells and molecules, periphe -Abstract Truncated-

oncology
[Rare diseases: unraveling the biological bases to find future therapies]

Mercedes Serrano

Abstract:Rare diseases are characterized by low prevalence and high complexity, affecting millions globally. Although technologies like massive sequencing improve diagnose, therapeutic options remain largely symptomatic or palliative, with few curative treatments approved. In the context of rare diseases, especially genetic neurodevelopmental disorders, therapy development faces obstacles such as phenotypic variability, diverse molecular mechanisms, and complexities in assessing neurodevelopment in natural history and clinical trials. Current strategies include drug repositioning, biomarker development, and a multilateral approach in seeking solutions, offering hope. This work reviews various strategies in developing therapies, from gene therapy and epigenetic therapies to identifying biological targets.
Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet

Lucio Luzzatto,Julie Makani

DOI: https://doi.org/10.3389/fphar.2021.770640

IF: 5.6

2022-01-10

Frontiers in Pharmacology

Abstract:Rare diseases (RD) pose serious challenges in terms of both diagnosis and treatment. Legislation was passed in the US (1983) and in EU (2000) aimed to reverse the previous neglect of RD, by providing incentives for development of “orphan drugs” (OD) for their management. Here we analyse the current situation in Africa with respect to (1) sickle cell disease (SCD), that qualifies as rare in the US and in EU, but is not at all rare in African countries (frequencies up to 1–2%); (2) paroxysmal nocturnal haemoglobinuria (PNH), that is ultra-rare in Africa as everywhere else (estimated <10 per million). SCD can be cured by bone marrow transplantation and recently by gene therapy, but very few African patients have access to these expensive procedures; on the other hand, the disease-ameliorating agent hydroxyurea is not expensive, but still the majority of patients in Africa are not receiving it. For PNH, currently most patients In high income countries are treated with a highly effective OD that costs about $400,000 per year per patient: this is not available in Africa. Thus, the impact of OD legislation has been practically nil in this continent. As members of the medical profession and of the human family, we must aim to remove barriers that are essentially financial: especially since countries with rich economies share a history of having exploited African countries. We call on the Global Fund to supply hydroxyurea for all SCD patients; and we call on companies who produce ODs to donate, for every patient who receives an expensive OD in a high income country, enough of the same drug, at a symbolic price, to treat one patient in Africa.

pharmacology & pharmacy
Rare genetic diseases in India: Steps toward a nationwide mission program

Anjana Kar,P Sundaravadivel,Ashwin Dalal

DOI: https://doi.org/10.1007/s12038-024-00430-1

2024-02-20

Journal of Biosciences

Abstract:Rare genetic diseases are rare by themselves with prevalence of 1 in 25,000, but collectively they are a significant cause of morbidity and mortality. Till date, collectively there are more than 9,000 rare diseases documented, which impose a devastating impact on patients, their families, and the healthcare system, including enormous societal burden. Obtaining a conclusive diagnosis for a patient with a rare genetic disease can be long and gruelling. For some patients it takes months or years to receive a definite diagnosis, and around 50% of the patients remain undiagnosed even with expert clinical and advanced high-end laboratory investigations. Owing to the large population and practice of consanguinity the Indian population is a pool of indigenous variants and unreported phenotypes or diseases. A mission program on pediatric rare diseases is an unparalleled initiative to study unique clinical conditions via the use of latest state-of-art technologies and with the combination of a mulit-omics approach. Our initiative will not only provide diagnosis to patients with rare disease but also build a platform for translational research for rare disease screening, management, and treatment.

biology
Inclusion and exclusion in the globalisation of genomics; the case of rare genetic disease in Brazil

Sahra Gibbon,Waleska Aureliano

DOI: https://doi.org/10.1080/13648470.2017.1381230

2018-01-02

Anthropology and Medicine

Abstract:Within the context of a globalising agenda for genetic research where 'global health' is increasingly seen as necessarily informed by and having to account for genomics, the focus on rare genetic diseases is becoming prominent. Drawing from ethnographic research carried out separately by both authors in Brazil, this paper examines how an emerging focus on two different arenas of rare genetic disease, cancer genetics and a class of degenerative neurological diseases known as Ataxias, is subject to and a product of the dynamics of inclusion and exclusion as this concerns participation in research and access to health care. It examines how in these different cases 'rarenesss' has been diversely situated and differently politicised and how clinicians, patients and their families grapple with the slippery boundaries between research, rights to health and the limits of care, therapy or prevention. It illustrates how attention to rare genetic disease in Brazil emerges at the intersection of a particular history of genetic research and public health infrastructure, densely complicated feedback loops between clinical care and research, patient mobilisation around the 'judicialisation' of health and recent state legislation regarding rare disease in Brazil. It highlights the relevance of local configurations in the way rare genetic disease is being made relevant for and by different communities.

anthropology,public, environmental & occupational health,social sciences, biomedical
Oncology nursing specialty across Latin America: struggle and achievements past and present

Dorian Rene Navarro Díaz,Carla Gonçalves Dias,Gustavo Rodriguez-Rodriguez,Esteban Sánchez Huaiquimil,Merí Isabel Ordoñez Sigcho,Humberto Elizalde Ordoñez,Melitta Cosme,Maria Constanza Celano,Evelyn Ramos,Julia Challinor,María Fernanda Olarte-Sierra

DOI: https://doi.org/10.21037/apm-22-1133

2024-03-22

Annals of Palliative Medicine

Abstract:BACKGROUND: Latin America (LATAM) is a large region from Mexico to southern Patagonia in Chile and includes most islands in the Caribbean where Spanish is an official language. Efforts to address nursing specialization in the care of patients with cancer throughout the cancer continuum are described in narratives of oncology nursing struggles and achievements from eight Latin American countries.METHODS: Contributions by authors from Mexico, Costa Rica, Ecuador, Brazil and Chile are complemented by interview data (in Spanish by a bilingual medical anthropologist) to share the history and present status in the Dominican Republic, Peru and Argentina.RESULTS: We present stories of the pioneers of oncology nursing and a brief description of health systems in several of the included countries to show the disparate approaches towards cancer control and the context in which the oncology nurses work. We include key demographics and cancer data from the highlighted countries. We follow with descriptions of the formation and importance of oncology nursing associations/ societies and share the history of oncology nursing education efforts, scopes of practice and recommendations for improvement in oncology nursing.CONCLUSIONS: Despite the challenges, oncology nurse leaders across LATAM are determined to raise the standards of care with structured specialization education/training, and to create advanced practice oncology nursing roles. It is critical that the achievements of oncology nurses are nationally acknowledged and appropriately compensated by governments and national and local authorities. The future is now for oncology nursing to be recognized as a critical specialized healthcare workforce to effectively address the growing threat of cancer and to ensure optimal control of this public health crisis across the region.

health care sciences & services
Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action

Eduardo Mysler,Odirlei Andre Monticielo,Ibrahim Abdulrazaq Al-Homood,Chak Sing Lau,Heselynn Hussein,Yi-Hsing Chen

DOI: https://doi.org/10.1093/mr/roae001

2024-03-29

Modern Rheumatology

Abstract:ABSTRACT Lupus remains a disease with a low prioritisation in the national agendas of many countries in Latin America, the Middle East, and Asia-Pacific, where there is a dearth of rheumatologists and limited access to new or even standard lupus treatments. There is thus an important need for education, advocacy, and outreach to prioritise lupus in these regions to ensure that patients receive the care they need. This article reviews some of the specific challenges facing the care and management of people with lupus in these regions and suggests strategies for improving patient outcomes. Specifically, we review and discuss (with a focus on the aforementioned regions) the epidemiology of lupus; economic costs, disease burden, and effects on quality of life; barriers to care related to disease assessment; barriers to effective treatment, including limitations of standard treatments, high glucocorticoid use, inadequate access to new treatments, and low adherence to medications; and strategies to improve lupus management and patient outcomes. We hope that this represents a call to action to come together and act now for the lupus community, policymakers, health authorities, and healthcare professionals to improve lupus management and patient outcomes in Latin America, the Middle East, and Asia-Pacific.

rheumatology

Latin America sets out to end neglect of rare diseases

Discovery of novel genetic syndromes in Latin America: Opportunities and challenges

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America

Building a National Policy for Rare Disease in Brazil

Global Health for Rare Diseases Through Primary Care

[Rare diseases and undiagnosed diseases: advances in neurodevelopment]

Special Issue "Diagnosis and Treatment of Rare Diseases"

Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement

Advancing diagnosis and research for rare genetic diseases in Indigenous peoples

The importance of international collaboration for rare diseases research: a European perspective

Rare diseases: Insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis

Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Child Neurology Care in Latin America: Challenges and Potential Solutions

Editorial: Childhood leukemias in Latin America: epidemiology, causality, novel predictive profiles and therapeutic strategies

[Rare diseases: unraveling the biological bases to find future therapies]

Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet

Rare genetic diseases in India: Steps toward a nationwide mission program

Inclusion and exclusion in the globalisation of genomics; the case of rare genetic disease in Brazil

Oncology nursing specialty across Latin America: struggle and achievements past and present

Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action